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Background: Collagen type III glomerulopathy (Col3GP), also known as collagenofibrotic glomerulonephropathy, is
a rare renal disease with unknown pathogenesis that occurs in animals and humans. We recently described a
naturally occurring canine autosomal recessive model of Col3GP, and the aim of the present work was to study the
clinical features of canine Col3GP and compare with the human phenotype. In humans two different clinical
syndromes with different age at onset (child- or adulthood) have been observed. In children a more aggressive
course with familial occurrence is described, characterized by progressively increasing proteinuria, nephrotic
syndrome, hypertension and chronic renal failure. A markedly increased serum level of the aminoterminal
propeptide of type III procollagen (PIIINP) is considered a useful marker for the disease. Since Col3GP and
concurrent hypocomplementemia have been observed in humans, we also aimed to investigate if
hypocomplementemia was present in Col3GP affected dogs. A litter consisting of seven puppies, four Col3GP
affected and three healthy unaffected, was observed from the day of birth until the affected puppies developed a
mild or moderate renal azotemia.
Results: During the period of observation growth retardation, increasing blood pressure, progressive proteinuria,
azotemia, hypoalbuminemia, hypercholesterolemia and increased serum PIIINP were observed in all the affected
dogs. Hypocomplementemia was not detected. Affected dogs were euthanized between 109 and 144 days of age,
and pathological examinations revealed ascites and massive glomerular accumulations of collagen type III,
consistent with Col3GP.
Conclusions: Dogs with Col3GP develop juvenile chronic renal failure, preceded by nephrotic syndrome, elevated
serum PIIINP and hypertension, thus have similar clinical features as the juvenile Col3GP in humans. Further studies
of this naturally occurring canine phenotype may provide more information on the pathogenesis and genetics of
Col3GP in both animals and humans.
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NephropathyBackground
Collagen type III glomerulopathy (Col3GP), also known
as collagenofibrotic glomerulonephropathy, is a rare
renal disease that occurs in both humans and animals. It
is characterized by massive glomerular accumulations of
collagen type III. In humans, two different manifesta-
tions of the syndrome have been observed, with different
age at onset [1,2]. The adulthood version consists of per-
sisting proteinuria with or without hypertension, and a* Correspondence: runa.rortveit@nvh.no
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reproduction in any medium, provided the orslowly progressing renal impairment. The occurrence is
sporadic, although it has been observed in siblings [3].
In children, a more aggressive familial phenotype is de-
scribed, with progressively increasing proteinuria, neph-
rotic syndrome, hypertension and chronic renal failure
[4]. A marked elevation of the aminoterminal propeptide
of type III procollagen (PIIINP) in serum is characteris-
tic for Col3GP in humans. PIIINP is enzymatically
cleaved off during the synthesis of collagen type III and
released into the blood, thus increased serum levels of
PIIINP might indicate an increased metabolism of colla-
gen type III.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Body weights of healthy and affected puppies during the study period. The affected showed a decreased growth rate from
around six to eight weeks of age and weight increase ceased from around 12 weeks. Black line: Col3GP affected. Grey line: Col3GP unaffected.
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dogs [6-9], monkeys [10,11] and a cat [12], with clinical
signs like proteinuria and hypoproteinemia, and a vari-
able degree of renal failure. To the authors’ knowledge
blood pressure and serum PIIINP levels in Col3GP
affected animals have not been reported.
Two human cases of Col3GP and concurrent factor
H deficiency have been reported, and a possible con-
nection between Col3GP and defects in the comple-
ment system has been proposed [1,13]. Deficiency of
factor H leads to uncontrolled alternative pathway
complement activation causing hypocomplementemia
(low serum C3). In animals complement factor H de-
ficiency has previously been described to occur spon-
taneously only in the porcine species; in Norwegian
Yorkshire pigs [14] developing membranoproliferative
glomerulonephritis type II [15].
We recently described a naturally occurring canine auto-
somal recessive model of Col3GP [6], documenting that theFigure 2 Blood pressure in healthy and affected puppies. The systolic
increased during the study period and stabilized at a higher level than the
Col3GP unaffected.morphology of Col3GP in dogs and humans is similar. The
aim of the present study was to describe the clinical fea-
tures of canine Col3GP including determining serum levels
of PIIINP, and compare with the clinical features of the hu-
man variant of the disease. We also aimed to investigate if
hypocomplementemia is present in affected dogs.
Methods
Animals
A litter consisting of seven mixed-breed puppies was
studied. The litter was produced by cross mating two
dogs that previously had produced Col3GP affected off-
spring. Four of the puppies, two males and two females,
developed the disease. The remaining three puppies,
two males and a female, showed no clinical signs of dis-
ease during the observation period. The litter was ob-
served from the day of birth until the affected puppies
developed mild or moderate renal azotemia. When clin-
ical signs of discomfort appeared the affected puppies(a) and diastolic (b) blood pressures in the affected puppies gradually
healthy siblings. Black line: Col3GP affected. Grey line:
Table 1 UPC, serum albumin, SCr and BP in healthy and affected puppies at various time points during the study
period
UPC Serum albumin (g/L) SCr (μmol/L) Systolic BP/diastolic BP (mmHg)
Time pointa 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
Affectedb mean 1.7 10.4 10.9 8.5 19 18 16 17 40 51 131 174 116/64 146/96 156/115 154/111
SD 1.4 3.1 2.7 0.9 1 5 2 1 2 5 41 42 7/11 14/11 12/11 13/9
Healthyc mean 1.3 0.4 0.2 0.1 21 29 32 34 42 51 63 72 125/51 125/66 125/88 121/71
SD 0.9 0.3 0.1 0 1 1 2 2 1 5 3 3 19/17 6/11 7/14 2/5
P-valued 0.67 0.01 0.004 0.05 0.06 0.02 <0.001 0.003 0.12 0.98 0.03 0.18 0.60/0.34 0.03/0.02 0.01/0.04 0.18/0.07
a Time point 1, age 17-25 days; time point 2, age 65-66 days; time point 3, age 107 days; time point 4, age 135 days.
b n = 4 at time point 1-3 and n = 2 at time point 4.
c n = 3 at all time points.
d Group means were compared using a two-sided t-test with unequal variances.
UPC, urine protein:creatinin ratio; SCr, serum creatinine; BP, blood pressure; SD, standard deviation.
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vate homes at the age of ten weeks. Age at euthanasia
ranged from 109-144 days. During the observation
period the puppies lived in the kennel of the Norwegian
School of Veterinary Science (NVH), and they were
weaned at eight weeks of age. The feeding regime was
standardized for all the puppies during the observation
period. Commercial dry dog food for puppies was grad-
ually introduced from three weeks of age and water was
given ad libitum.
The study was approved by the Norwegian Animal
Research Authority and performed in accordance with
the National animal welfare rules and regulation for
research involving animals (LOV-2009-06-19-97/FOR-
1996-01-15-23).Figure 3 Urine protein:creatinine (UPC) ratio in affected and unaffect
age UPC increased rapidly in affected puppies, and the proteinuria was per
Col3GP unaffected.Clinical evaluations
The puppies were thoroughly observed every day. Every
other week all the puppies went through a physical
examination including measurement of blood pressure
and blood analyses. Due to the small body size of the
puppies, blood pressure measurements were not per-
formed until the puppies were 25 days of age. Analyses
of voided urine samples and body weight were recorded
weekly.
Systemic blood pressure was measured indirectly with
an oscillometric system (Cardell Veterinary Monitor 9401
BP, Sharn Veterinary Inc, Tampa, Florida), and the proced-
ure was standardized and performed by the same trained
veterinary nurse. The puppies were placed in a relaxed
position, either on the floor or on the lap of the personnel.ed puppies during the observation period. From around 50 days of
sistent at a high-magnitude level. Black line: Col3GP affected. Grey line:
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http://www.biomedcentral.com/1746-6148/9/218The cuff was applied below the elbow and cuff size
was assessed to be approximately 40% of the circum-
ference of the cuff site. Between three and six con-
secutive consistent values of systolic, diastolic and
mean arterial pressure were recorded. If a measured
value deviated markedly from the other values
this value would be discarded and additional mea-
surements made. The recorded blood pressure was
the average of at least three successful measurements.
Hypertension was diagnosed if systolic pressure ex-
ceeded 160 mmHg or diastolic pressure exceeded
100 mmHg.Figure 4 Determination of serum clinical chemistry in affected and un
affected puppies serum concentrations of creatinine (a) and urea (b) gradu
concentrations (c) were detected from around 50 days of age, and increas
affected). Increased serum concentrations of potassium (e) and inorganic p
Col3GP unaffected.Urine analysis included commercial dipstick analysis
(Krub; Kruuse, Marslev, Denmark), urine specific gravity
(USG) measured with a refractometer (URC-Ne, ATAGO,
Tokyo, Japan), and urine protein:creatinine ratio (UPC)
analyzed at the Central Laboratory, NVH.
Blood analyses included standard hematology and clin-
ical chemistry and were analyzed at the Central Labora-
tory, NVH.
In addition to the four affected puppies from the stud-
ied litter, three other Col3GP affected individuals from
the same pedigree contributed to the serum analyses of
PIIINP and C3, and eight healthy dogs of similar age,affected puppies during the observation period. Regarding the
ally increased from around 70 days of age. Decreased serum albumin
ed serum cholesterol (d) from around day 100 (in three of four
hosphate (f) were observed. Black lines: Col3GP affected. Grey lines:
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trol animals. Venous blood was collected into plain tubes,
allowed to clot at room temperature and after centrifuga-
tion the serum was transferred to plastic tubes and stored
at −80°C until analysis. PIIINP was determined using a
commercially available quantitative radioimmunoassay de-
signed for measurement of PIIINP in human serum, UniQ
PIIINP RIA (Orion Diagnostica, Espoo, Finland). This kit
has previously been validated for measurement of PIIINP
in canine serum [16]. Serum levels of C3 were assessed
using a commercially available immunoperoxidase assay
for determination of C3 in dog sera (ICL, Portland, OR).
Both assays were performed according to the manufac-
turers’ instructions. Assuming normal distributions group
means were compared using a two-sided t-test with
unequal variances. Due to an age effect on serum PIIINP
concentrations the statistical comparison regarding this an-
alyte was performed between two subgroups (n = 5) with
similar age, of healthy (mean age 102 days, range 73-141)
and affected (mean age 120 days, range 80-144).
Pathological examination
The affected puppies were autopsied immediately after
euthanasia. Renal tissue samples were prepared for
transmission electron microscopy in addition to light
microscopy. For light microscopy, tissues were fixed in
10% buffered formaldehyde and embedded in paraffin,
and 2-4 μm thick sections of renal tissue were stained
with hematoxylin and eosin, periodic acid-Schiff and van
Gieson, and studied in a Nikon Eclipse 50i microscope.
Photomicrographs were captured with a Nikon DS-Fi1
camera using NIS Elements Basic Research software. For
transmission electron microscopy, tissues were prefixed in
3% glutaraldehyde in 0.1 M cacodylatebuffer, post-fixed in
osmium, dehydrated in ethanol and embedded in epon.Figure 5 Serum concentrations of precollagen III peptide (PIIINP) in s
revealed significantly higher serum levels than the healthy controls (t-test,
the older ones.Semithin sections were stained with toluidine blue and
examined under the light microscope for selection of
glomeruli. Ultrathin sections were stained with uranyl
acetate and lead citrate, and the specimens were observed
in a Phillips CM 10 transmisson electron microscope.
Results
Clinical findings
Physical examinations, body weight, blood pressure and
analysis of blood and urine samples were initially with-
out remarks for all the puppies and remained unremark-
able for the healthy ones.
From six to eight weeks of age the affected dogs showed
a decreased growth rate and became thinner than their
healthy siblings, and from 12 weeks of age weight increase
ceased (Figure 1). Increases in systolic and diastolic blood
pressures were observed (Figure 2a and b), and higher
blood pressure values were found in affected dogs com-
pared to the healthy siblings (Table 1). Proteinuria was
first detected by analysis of UPC on day 44 (two dogs) and
51 (two dogs). The proteinuria was persistent and rapidly
increased before stabilizing at a high level (Figure 3), and
was markedly higher than in the healthy littermates
(Table 1). The ability to concentrate urine gradually de-
creased. After approximately 90 days of age the USG
values of the affected puppies did not exceed 1,030, and at
the last evaluation before euthanasia USG varied from
1,018 to 1,023. Urine dipstick analysis showed, in addition
to proteinuria, occasional mild hematuria and glycosuria
in absence of hyperglycemia.
Serum analysis revealed progressively increasing cre-
atinine and urea values (Figure 4a and b, Table 1),
decreasing albumin values (Figure 4c, Table 1), and an
increased cholesterol level in three of the puppies from
approximately 100 days of age (Figure 4d). Elevatedeven affected and eight healthy controls. The affected dogs
P = 0,01). In the control group younger puppies had higher levels than
Figure 6 Serum concentrations of C3 in 7 affected and 8
healthy control dogs. There was no significant difference in serum
levels of C3 between the two groups (t-test, P = 0,24).
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phosphate (Figure 4f ) were also observed.
Serum concentrations of PIIINP in seven affected and
eight control animals are shown in Figure 5, and serum
levels of PIIINP were significantly higher (t-test, P = 0,01) in
the affected dogs (mean 220 ng/ml, standard deviation
3 ng/ml) than in the controls (mean 151 ng/ml, standard
deviation 37 ng/ml). Younger puppies in the control group
had higher levels of serum PIIINP than the older ones.
There was no significant difference between serum levels of
C3 in affected and control dogs (t-test, P = 0,24) (Figure 6).
Affected puppies were euthanized at 109 (n = 1), 123
(n = 1) and 144 (n = 2) days of age.
Pathological findings
Necropsy revealed reduced muscle mass and a moderate
ascites in all four affected puppies. The kidneys wereFigure 7 Light microscopic appearance of affected glomeruli. (a) The
extracellular eosinophilic fibrillar material (hematoxylin and eosin, ×20). (b)
suggesting a collagenous nature of the deposited material (van Gieson, ×2pale and firm with granular surfaces. Light microscopic
studies showed diffuse glomerular lesions consisting of a
severe expansion of the mesangium and the capillary
walls by a homogenous eosinophilic material, and a vari-
able degree of mesangial and endocapillary hypercellu-
larity (Figure 7). There was mild to moderate tubular
atrophy and severe periglomerular and moderate inter-
stitial fibrosis. Occasionally interstitial infiltrations of
inflammatory cells were found. By transmission electron
microscopy massive glomerular accumulations of fibril-
lar collagen was identified in the subendothelial and
mesangial space, consistent with Col3GP.
Discussion
The Col3GP affected puppies in the present study devel-
oped nephrotic syndrome, characterized by heavy pro-
teinuria, hypoalbuminemia, hypercholesterolemia and
ascites. The proteinuria was severe and of glomerular
origin [17] and the protein loss rapidly exceeded the
protein synthesizing capacity, causing hypoalbuminemia.
The pathological findings were consistent with Col3GP
and identical to the lesions previously described in other
dogs from the same pedigree [6].
Previously, three case reports describing canine Col3-
GP have been published [7-9]. One report describes
three puppies from a litter of Newfoundland dogs, two
of them two months old and the third one year old, that
developed renal disease characterized by growth retard-
ation, anorexia and proteinuria. The puppies were eutha-
nized due to bad prognosis, and characteristic renal
lesions of Col3GP were disclosed by light microscopy
and transmission electron microscopy. However, immu-
nohistochemistry to confirm the presence of collagen
type III in the glomeruli was not performed. In a previ-
ous litter from the same dam and sire, two of the pup-
pies had died at a young age, strongly supporting a
hereditary disease [9]. The two other case reports de-
scribe a seven month old mongrel dog with growthmesangium and the capillary walls are expanded by deposited
The abnormal glomerular material stain red using van Gieson stain,
0). Bar = 100 μm.
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sented with anorexia at three years of age [7]. Both cases
had a mortal outcome and at necropsy the dogs had
pathological changes characteristic of Col3GP. All the
described cases showed increased serum creatinine, urea,
hypoalbuminemia and proteinuria. With exception of
the three year old Shiba Inu, all cases showed juvenile-
onset renal disease, in accordance with the litter in the
present study, and the four previously reported cases
from the same pedigree [6].
In humans, two kinds of Col3GP have been described,
one in children and one in adults [1,2]. In children the
disease tends to be more aggressive with a familial oc-
currence. Gubler et al. reported ten cases [4], including
three pairs of siblings. The patients were from four
months to 13 years of age at presentation. All showed
proteinuria, six had microscopic hematuria, five were
hypertensive, three were anemic and four developed
renal insufficiency. In nine of the ten cases the disease
followed an unremitting course [4]. The canine variant
of Col3GP, with proteinuria, hypertension and early oc-
currence of renal impairment closely resembles the
childhood version of Col3GP. However, hematuria and
anemia seems to be more common in human cases than
in affected dogs.
Elevated serum levels of PIIINP in Col3GP affected
dogs compared to healthy age-matched controls were
observed in the present study. Increased serum PIIINP
is well described in Col3GP affected humans [18-22],
but has so far not been reported in animals. Regarding
the control group, the younger puppies had higher
serum PIIINP concentrations than the older ones, and
the serum levels declined with increasing age at sam-
pling. This coincides with studies in humans [23] and
dogs [16] showing that serum levels of PIIINP are higher
in young growing individuals than in adults. The effect
of age on serum levels of PIIINP limits its value as a
marker of disease in young individuals, and emphasizes
the need for age-specific reference intervals. This prob-
lem was also reflected in the present study where the
differences in serum levels between affected and un-
affected dogs became more apparent with increasing
age. The serum levels were determined using a human
kit which was validated by Schuller et al. for measure-
ments of canine PIIINP [16]. The majority of the sam-
ples exceeded the range for which the kit was validated
and therefore further validation is needed to precisely
determine serum concentrations of PIIINP in dogs.
However, since all the samples were treated in the same
manner the results may be regarded as valid for com-
parison between the groups. Schuller et al. did not show
differences in serum levels of PIIINP in dogs with
chronic renal failure compared to healthy dogs [16]. In
human cases, serum levels vary strongly. In patients withchronic renal failure a doubling was seen compared to
healthy controls [24], and in patients with Col3GP a
hundredfold increase has been observed [25]. The
pathological significance of the markedly elevated serum
PIIINP in Col3GP affected humans and dogs compared
to other types of chronic renal failure is unknown.
Glomerular collagen type III synthesis occurs in Col3GP
exclusively, however, in chronic kidney disease, regard-
less of cause, the amount of collagen type III synthesized
in the renal interstitium is often even more extensive.
Further studies on affected dogs should be performed to
clarify the pathological mechanisms of this disease,
including increased serum PIIINP.
Two human cases of Col3GP with concurrent factor H
deficiency resulting in hypocomplementemia have been
described, suggesting an association between Col3GP
and defects in the complement system [1,13]. In the
present study there was no difference between levels of
C3 in affected dogs and healthy controls, excluding asso-
ciated hypocomplementemia.
Conclusions
The present study describes the clinical signs of canine
Col3GP, characterized by nephrotic syndrome, increased
serum PIIINP and hypertension. The clinical course pro-
gressed to chronic renal failure, and resembled Col3GP
occurring in children. Associated hypocomplementemia
was excluded. Further studies of this naturally occurring
canine phenotype may have the potential to provide
more information on the pathogenesis and genetics of
Col3GP in both animals and humans.
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